Isoharringtonine is a natural product with significant anti-cancer activity. It is a diterpene alkaloid isolated from the seeds of the tree *Cephalotaxus harringtonia*. The compound has been shown to exhibit potent activity against various cancer cell lines, including leukemia, lymphoma, and solid tumors. Isoharringtonine works by inhibiting protein synthesis, specifically targeting the elongation factor 2 (EF-2), a key protein involved in the translation of mRNA into proteins. This mechanism of action differentiates it from other anticancer drugs and makes it a promising candidate for further investigation and potential therapeutic development. Although the synthesis of Isoharringtonine has been achieved, it is a complex and challenging process. Due to its unique biological activity and promising anticancer properties, Isoharringtonine remains an active area of research, with efforts focused on understanding its mechanism of action, developing more efficient synthetic routes, and exploring its potential in clinical applications.'
isoharringtonine: alkaloid from Cephalotaxus harringtonia [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Cephalotaxus | genus | A plant genus of the family TAXACEAE, order Pinales, class Pinopsida, division TRACHEOPHYTA. Members contain homoharringtonine.[MeSH] | Taxaceae | A plant family of the order Pinales, class Pinopsida, division TRACHEOPHYTA.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 73492 |
| CHEMBL ID | 1969433 |
| SCHEMBL ID | 14698126 |
| MeSH ID | M0041924 |
| Synonym |
|---|
| 26833-86-3 |
| nsc141634 , |
| cephalotaxine,3-dihydroxy-2-(3-methylbutyl)butanedioate (ester) |
| isoharringtonine |
| cephalotaxine,3-dihydroxy-2-(3-methylbutyl)butanedioate (ester), [3(2r,3s)]- |
| cephalotaxine,3-dihydroxy-2-(3-methylbutyl)butanedioate (ester),[3(2r,3s)]- |
| nsc-141634 |
| cephalotaxine, 4-methyl-2,3-dihydroxy-2-(3-methylbutyl)butanedioate (ester), (3-(2r,3s))- |
| 4-methylcephalotaxine 2,3-dihydroxy-2-(3-methylbutyl)butanedioate ester |
| cephalotaxine, 4-methyl 2,3-dihydroxy-2-(3-methylbutyl)butanedioate (ester), (3(2r,3s))- |
| cephalotaxine, 4-methyl (2r,3s)-2,3-dihydroxy-2-(3-methylbutyl)butanedioate (ester) |
| o1-(methoxy[?]yl) o4-methyl (2r,3s)-2,3-dihydroxy-2-isopentyl-butanedioate |
| NCI60_000918 |
| SCHEMBL14698126 |
| CHEMBL1969433 |
| 1-o-[(2s,3s,6r)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] 4-o-methyl (2r,3s)-2,3-dihydroxy-2-(3-methylbutyl)butanedioate |
| DTXSID401316729 |
| CS-0226965 |
| HY-N9954 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.17) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||